Drug intelligence / Profile preview

DWRX5006

Development stage: Preclinical
Lead developer: Daewoong Therapeutics
Modality: DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Transdermal

Overview

DWRX5006 is a polynucleotide-based microneedle patch under development by Daewoong Therapeutics for aesthetic applications. Utilizing Daewoong's proprietary CLOPAM (Closed Packed Aero-pressured Microneedle) drug-delivery platform, the patch is designed to deliver polynucleotides transdermally to promote skin rejuvenation and tissue regeneration. The dissolving microneedle technology allows for precise, pain-free delivery of the active ingredient directly into the skin, offering a needle-free alternative to traditional injectable skin boosters. DWRX5006 is designed for once-weekly application and is engineered to maintain stability at room temperature, eliminating the need for cold-chain storage.

Beyond the preview

Go deeper on DWRX5006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWRX5006.

Explore the full profile